Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
NEW YORK, April 23, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities between September 12, 2016 and February 27, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/celgene-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the trials for GED-0301 suffered from fatal design defects, such that GED-0301 had failed to demonstrate meaningful clinical efficacy; (3) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (4) the clinical and nonclinical pharmacology data in Celgene's new drug application ("NDA") for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.
If you suffered a loss in Celgene you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/celgene-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
